SLNO

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Soleno Therapeutics Inc

NASDAQ | SLNO

64.27

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$3.39B

Market Cap

-

P/E Ratio

-4.22

EPS

$90.32

52 Week High

$41.50

52 Week Low

HEALTHCARE

Sector

SLNO Chart

Recent Chart
Price Action

SLNO Technicals

Tags:

SLNO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$184M
Selling General And Administrative $106M
Research And Development $79M
Operating Expenses $188M
Investment Income Net -
Net Interest Income $12M
Interest Income $12M
Interest Expense $231K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$176M
Income Tax Expense -$176M
Interest And Debt Expense -
Net Income From Continuing Operations -$176M
Comprehensive Income Net Of Tax -
Ebit -$184M
Ebitda -$174M
Net Income -$176M

Revenue & Profitability

Earnings Performance

SLNO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $331M
Total Current Assets $294M
Cash And Cash Equivalents At Carrying Value $88M
Cash And Short Term Investments $88M
Inventory -
Current Net Receivables -
Total Non Current Assets $37M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $6.8M
Intangible Assets Excluding Goodwill $6.8M
Goodwill -
Investments -
Long Term Investments $27M
Short Term Investments $204M
Other Current Assets $2.5M
Other Non Current Assets -
Total Liabilities $86M
Total Current Liabilities $19M
Current Accounts Payable $8.9M
Deferred Revenue -
Current Debt -
Short Term Debt $526K
Total Non Current Liabilities $67M
Capital Lease Obligations $3M
Long Term Debt $50M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $53M
Other Current Liabilities $9.3M
Other Non Current Liabilities $15M
Total Shareholder Equity $245M
Treasury Stock -
Retained Earnings -$452M
Common Stock $46K
Common Stock Shares Outstanding $40M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$69M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2M
Capital Expenditures $218K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$226M
Cashflow From Financing $213M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$176M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$184M
Selling General And Administrative $106M
Research And Development $79M
Operating Expenses $188M
Investment Income Net -
Net Interest Income $12M
Interest Income $12M
Interest Expense $231K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$176M
Income Tax Expense -$176M
Interest And Debt Expense -
Net Income From Continuing Operations -$176M
Comprehensive Income Net Of Tax -
Ebit -$184M
Ebitda -$174M
Net Income -$176M

SLNO News

SLNO Profile

Soleno Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, dedicated to developing innovative therapies for rare diseases. With a strong emphasis on addressing unmet medical needs, Soleno leverages its proprietary drug development platform to advance treatments through clinical trials. The company's commitment to therapeutic innovation positions it as a key player in the rare disease space, making it an intriguing investment opportunity for institutional investors seeking exposure to cutting-edge biopharmaceutical advancements.

VHAI
-25.00%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
NVTS
+21.14%
$9.97
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
APLD
+0.73%
$34.24
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
AMD
+0.40%
$215.76
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
RR
+8.95%
$6.45
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
IONQ
+16.19%
$82.09
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
MARA
+8.52%
$20.23
NOK
-1.31%
$5.25
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30
VHAI
-25.00%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
NVTS
+21.14%
$9.97
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
APLD
+0.73%
$34.24
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
AMD
+0.40%
$215.76
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
RR
+8.95%
$6.45
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
IONQ
+16.19%
$82.09
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
MARA
+8.52%
$20.23
NOK
-1.31%
$5.25
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.